Effects of sesquiterpene, flavonoid and coumarin types of compounds from Artemisia annua L. on production of mediators of angiogenesis

Pharmacological Reports

Volumn 65, Issue 2, 2013, Pages 410-420

  Zhu, Xiaoxin X ^a   Yang, Lan ^a   Li, Yujie J ^a   Zhang, Dong ^a   Chen, Ying ^a   Kostecká, Petra ^b   Kmoníéková, Eva ^c   Zídek, Zdeník ^b  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiogenic factors; Artemisia annua L.; Cytokines; Nitric oxide; Prostaglandins

Indexed keywords

4 METHYLESCULETIN; ARTEANNUIN B; ARTEMISIA ANNUA EXTRACT; ARTEMISINIC ACID; ARTEMISININ; CASTICIN; CHRYSOSPLENOL D; COUMARIN; CYCLOOXYGENASE 2; DIHYDROARTEMISININ; FLAVONOID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE; PROSTAGLANDIN E2; SESQUITERPENE; SESQUITERPENE LACTONE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTEMISIA ANNUA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; METASTASIS; NONHUMAN; PERITONEUM CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TUMOR GROWTH;

EID: 84879360823     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71016-8     Document Type: Article

References (57)

1. Al-Waili NS: A potential concept in the management of tumors with modulation of prostaglandin, nitric oxide and antioxidants. ScientificWorldJournal, 2007, 7, 466-478.
2. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D: Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett, 2003, 552, 141-144.
3. Aung W, Sogawa C, Furukawa T, Saga T: Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor model evaluated by conventional methods and optical imaging. Anticancer Res, 2011, 31, 1549-1558.
4. Awale S, Linn TZ, Li F, Tezuka Y, Myint A, Tomida A, Yamori T et al.: Identification of chrysoplenetin from Vitex negundo as a potential cytotoxic agent against PANC-1 and a panel of 39 human cancer cell lines (JFCR-39). Phytother Res, 2011, 25, 1770-1775.
5. Benelli R, Lorusso G, Albini A, Noonan DM: Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des, 2006, 12, 3101-3115.
6. Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G: Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol Rep, 2005, 14, 1599-1603.
7. Bertea CM, Freije JR, van der Woude H, Verstappen FW, Perk L, Marquez V, De Kraker JW et al.: Identification of intermediates and enzymes involved in the early steps of artemisinin biosynthesis in Artemisia annua. Planta Med, 2005, 71, 40-47.
8. Bradbury D, Clarke D, Seedhouse C, Corbett L, Stocks J, Knox A: Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem, 2005, 280, 29993-30000.
9. Brown GD: The biosynthesis of artemisinin (Qinghaosu) and the phytochemistry of Artemisia annua L. (Qinghao). Molecules, 2010, 15, 7603-7698.
10. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-257.
11. Cascone T, Gridelli C, Ciardiello F: Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol, 2007, 19, 98-102.
12. Ding YB, Shi RH, Tong JD, Li XY, Zhang GX, Xiao WM, Yang JG et al.: PGE2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system. Exp Oncol, 2005, 27, 108-113.
13. Ferreira JF, Luthria DL, Sasaki T, Heyerick A: Flavonoids from Artemisia annua L. as antioxidants and their potential synergism with artemisinin against malaria and cancer. Molecules, 2010, 15, 3135-3170.
14. Freitas S, Costa S, Azevedo C, Carvalho G, Freire S, Barbosa P, Velozo E et al.: Flavonoids inhibit angiogenic cytokine production by human glioma cells. Phytother Res, 2011, 25, 916-921.
15. Grandinetti CA, Goldspiel BR: Sorefanib and sunitinib: novel targered therapies for renal cell cancer. Pharmacotherapy, 2011, 27, 1125-1144.
16. Haïdara K, Zamir L, Shi QW, Batist G: The flavonoid casticin has multiple mechanisms of tumor cytotoxicity action. Cancer Lett, 2006, 242, 180-190.
17. He Q, Shi J, Shen XL, An J, Sun H, Wang L, Hu YJ et al.: Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biol Ther, 2010, 9, 819-824.
18. Higa S, Hirano T, Kotani M, Matsumoto M, Fujita A, Suemura M, Kawase I, Tanaka T: Fisetin, a flavonol, inhibits TH2-type cytokine production by activated human basophils. J Allergy Clin Immunol, 2003, 111, 1299-1306.
19. Hirano T, Higa S, Arimitsu J, Naka T, Shima Y, Ohshima S, Fujimoto M et al.: Flavonoids such as luteolin, fisetin and apigenin are inhibitors of interleukin-4 and interleukin-13 production by activated human basophils. Int Arch Allergy Immunol, 2004, 134, 135-140.
20. Chen HH, Zhou HJ, Wu GD, Lou XE: Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology, 2004, 71, 1-9.
21. Chen T, Hwang H, Rose ME, Nines RG, Stoner GD: Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun. Cancer Res, 2006, 66, 2853-2859.
22. Iqbal S, Lenz HJ: Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol, 2004, 54, Suppl 1, S32-S39.
23. Jackson SA, Sahni S, Lee L, Luo Y, Nieduzak TR, Liang G, Chiang Y et al.: Design, synthesis and characterization of a novel class of coumarin-based inhibitors of inducible nitric oxide synthase. Bioorg Med Chem, 2005, 13, 2723-2739.
24. Kim HK, Cheon BS, Kim YH, Kim SY, Kim HP: Effects of naturally occurring flavonoids on nitric oxide production in the macrophage cell line RAW264.7 and their structure-Activity relationships. Biochem Pharmacol, 1999, 58, 759-765.
25. Konkimalla VB, Blunder M, Korn B, Soomro SA, Jansen H, Chang W, Posner GH et al.: Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW264.7 mouse macrophage cells. Nitric Oxide, 2008, 19, 184-191.
26. Krishna S, Bustamante L, Haynes RK, Staines HM: Artemisinins: their growing importance in medicine. Trends Pharmacol Sci, 2008, 29, 520-527.
27. Leung KN, Leung PY, Kong LP, Leung PK: Immunomodulatory effects of esculetin (6,7-dihydroxycoumarin) on murine lymphocytes and peritoneal macrophages. Cell Mol Immunol, 2005, 2, 181-188.
28. Lewis CE, Leek R, Harris A, McGee JO: Cytokine regulation of angiogenesis in breast cancer: the role of tumor-Associated macrophages. J Leukoc Biol, 1995, 57, 747-751.
29. Li B, Zhang R, Li J, Zhang L, Ding G, Luo P, He S et al.: Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kB activation. Int Immunopharmacol, 2008, 8, 379-389.
30. Li WX, Cui CB, Cai B, Wang HY, Yao XS: Flavonoids from Vitex trifolia L. inhibit cell cycle progression at G2/M phase and induce apoptosis in mammalian cancer cells. J Asian Nat Prod Res, 2005, 7, 615-626.
31. Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS: Macrophage oxidation of L-Arginine to nitrite and nitrate. Biochemistry, 1988, 27, 8706-8711.
32. Matsuda H, Morikawa T, Ohgushi T, Ishiwada T, Nishida N, Yoshikawa M: Inhibitors of nitric oxide production from the flowers of Angelica furcijuga: structures of hyuganosides IV and V. Chem Pharm Bull (Tokyo), 2005, 53, 387-392.
33. Ogino H, Yano S, Kakiuchi S, Yamada T, Ikuta K, Nakataki E, Goto H et al.: Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett, 2008, 265, 55-66.
34. Oklu R, Walker TG, Wicky S, Hesketh R: Angiogenesis and current antiangiogenic strategies for the treatment of cancer. J Vasc Interv Radiol, 2010, 21, 1791-1805.
35. Olszanecki R, Gêbska A, Kozlovski VI, Gryglewski RJ: Flavonoids and nitric oxide synthase. J Physiol Pharmacol, 2002, 53, 571-584.
36. Ono M, Yanaka T, Yamamoto M, Ito Y, Nohara T: New diterpenes and norditerpenes from the fruits of Vitex ro-tundifolia. J Nat Prod, 2002, 65, 537-541.
37. Raghav SK, Gupta B, Shrivastava A, Das HR: Inhibition of lipopolysaccharide-inducible nitric oxide synthase and IL-1b through suppression of NF-kB activation by 3-(1'-1'-dimethyl-Allyl)-6-hydroxy-7-methoxy-coumarin isolated from Ruta graveolens L. Eur J Pharmacol, 2007, 560, 69-80.
38. Sakurai T, Kudo M: Signaling pathways governing tumor angiogenesis. Oncology, 2011, 81, Suppl 1, 24-29.
39. Singh NP, Panwar VK: Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther, 2006, 5, 391-394.
40. Song X, Chen Y, Sun Y, Lin B, Qin Y, Hui H, Li Z et al.: Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide. Pharmacol Rep, 2012, 64, 1189-1199.
41. Toomey DP, Murphy JF, Conlon KC: COX-2, VEGF and tumour angiogenesis. Surgeon, 2009, 7, 174-180.
42. Uneda S, Hata H, Matsuno F, Nagasaki A, Harada N, Mitsuya Y, Matsuzaki H, Mitsuya H: A nitric oxide synthase inhibitor, NG-nitro-l-Arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. Br J Haematol, 2003, 120, 396-404.
43. Wallaart TE, Pras N, Beekman AC, Quax WJ: Seasonal variation of artemisinin and its biosynthetic precursors in plants of Artemisia annua of different geographical origin: proof for the existence of chemotypes. Planta Med, 2000, 66, 57-62.
44. Wang GY, Ji B, Wang X, Gu JH: Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer. World J Gastroenterol, 2005, 11, 3830-3833.
45. Wang J, Zhou H, Zheng J, Cheng J, Liu W, Ding G, Wang L et al.: The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release. Antimicrob Agents Chemother, 2006, 50, 2420-2427.
46. Wang JX, Hou LF, Yang Y, Tang W, Li Y, Zuo JP: SM905, an artemisinin derivative, inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kB pathways in RAW264.7 macrophages. Acta Pharmacol Sin, 2009, 30, 1428-1435.
47. Watanabe K, Kawamori T, Nakatsugi S, Wakabayashi K: COX-2 and iNOS, good targets for chemoprevention of colon cancer. Biofactors, 2000, 12, 129-133.
48. Witaicenis A, Seito LN, Di Stasi LC: Intestinal antiinflammatory activity of esculetin and 4-methylesculetin in the trinitrobenzenesulphonic acid model of rat colitis. Chem Biol Interact, 2010, 186, 211-218.
49. Wu XH, Zhou HJ, Lee J: Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion. Anticancer Drugs, 2006, 17, 839-848.
50. XuW, Liu LZ, Loizidou M, Ahmed M, Charles IG: The role of nitric oxide in cancer. Cell Res, 2002, 12, 311-320.
51. Yance DRJ, Sagar SM: Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther, 2006, 5, 9-29.
52. Zeng Q-P, Zhang P-Z: Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. Nitric Oxide, 2011, 24, 110-112.
53. Zhai DD, Zhong JJ: Simultaneous analysis of three bioactive compounds in Artemisia annua hairy root cultures by reversed-phase high-performance liquid chromatography-diode array detector. Phytochem Anal, 2010, 21, 524-530.
54. Zhang D, Yang L, Yang L-X, Wang M-Y, Tu Y-Y: Determination of artemisinin, arteannuin B and artemisinic acid in Herba Artemisiae Annuae by HPLC-UV-ELSD. Acta Pharmaceut Sinica, 2007, 42, 978-981.
55. Zhou HJ, Wang WQ, Wu GD, Lee J, Li A: Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol, 2007, 47, 131-138.
56. Zhu Z, Witte L: Inhibition of tumor growth and metastasis by targeting tumor-Associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs, 1999, 17, 195-212.
57. Ziche M, Morbidelli L: Molecular regulation of tumour angiogenesis by nitric oxide. Eur Cytokine Netw, 2009, 20, 164-170.